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                                  ABSTRACT 
 
Growth cones direct axon pathfinding during neural development by detecting 
environmental stimuli, known as axon guidance molecules. In vitro studies have shown 
inhibitory axon guidance molecules to cause growth cones to change morphology to what 
is called a collapsed growth cone. Lysophosphatidic acid (LPA) has been demonstrated to 
collapse growth cones in culture, and thus it may act as an inhibitory molecule. However, 
identification of what LPA receptor is responsible for this physiological response is 
unknown. To investigate which receptor elicits collapse, we focused on LPA receptor-4 
(LPA4) by designing a CRISPR construct to mutate Lpar4 in chick retinal ganglion cells 
(RGCs). Through retinal injections, we will introduce our CRISPR construct and isolate 
mutated retinal tissue to observe whether mutating Lpar4 abolishes RGC growth cone 
collapse. Preliminary data suggests our injection delivery system can successfully target 
RGCs. Moreover, we have successfully cloned five guide RNAs (gRNA) and obtained 
sequence results from gRNAs1-3 that show gRNA 1 and 2 have a high mutation rate in a 
DF1-Cas9 cell line.  
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Chapter 1                              INTRODUCTION 
 
1.1 Glaucoma, Central Nervous System Injury 
 Research estimates that over 3 million Americans will suffer from glaucoma by 
2020 and it is estimated that a large population of individuals have glaucoma but have not 
received a diagnosis (Friedman et al., 2004). Individuals who suffer from glaucoma, optic 
nerve damage, or injury to the central nervous system (CNS, brain and spinal cord) will 
have permanent nerve damage. The major issue is nerves in the CNS do not regenerate 
once damage has occurred. One prominent model for nerve regeneration is the visual 
system since these neurons travel long distances towards their target during embryonic 
development. As a result, this makes understanding development of visual neurons by 
how they pathfind and organize an essential model for uncovering molecular cues that 
could potentially be induced/reduced after CNS damage to facilitate nerve regeneration. 
How neural circuits are established during development and how specific neural 
connections are made with their synaptic partner remains an intriguing and pivotal 
question in neurobiology. 
Unfortunately, there are no current therapeutic treatments to help aid nerve 
regeneration. Therefore, research has investigated why the CNS lacks regeneration 
completely. One significant reason is that many inhibitory factors exist within our CNS 
physiology (e.g., Semaphorins, Lysophospholipids, glial scarring, or extracellular matrix 
molecules) (Pfeiffenberger et al., 2006; Schwab and Theornen, 1985; Schwab and 
Caroni, 1988). The inability for CNS nerves to regenerate is why biomedical research 
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must understand the underlying factors within our physiology which prevents 
regeneration. 
The issue of why regeneration in the CNS is completely absent has been an 
ongoing investigation since the early 1900s. Early in vitro studies with dissociated 
sensory or sympathetic neurons cultured using adult rat sciatic (peripheral nervous 
system—PNS) or optic (CNS) nerves revealed differences in regenerative properties 
between PNS and CNS nerves. In fact, axons were found in abundance among sciatic 
nerve tissue, whereas neurite outgrowth among optic nerve tissue was absent (Schwab 
and Thoenen, 1985). Soon afterwards, Schwab and Caroni (1988) would discover that 
nonpermissive substrates are expressed after developmental periods within the CNS, 
thereby inhibiting future neurite outgrowth. This nonpermissive substrate included 
myelin produced by oligodendrocytes (CNS) to surround axons in order to enhance 
propagation of action potentials between neurons. Within the PNS, Schwann cells handle 
myelin production and do not restrict neurite outgrowth in vitro (Schwab and Caroni, 
1988). The unique differences between the nervous system demonstrates that there are 
many more biological factors that need to be investigated to provide us with a better 
understanding of how neuronal cells communicate within their environment.  
 
1.2  Axon pathfinding during development 
During neural circuit formation, axons must navigate through various tissues, 
which means being able to respond to a changing environment. Axons of neurons 
navigate during pathfinding, find specific target areas, identify target neurons, and 
establish functioning synapses with appropriate synaptic targets. A prominent model for 
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nerve growth is the visual system since it is well-established that visual neurons organize 
in a highly specific topographic map (for review, see Erskine and Herrera, 2007). Retinal 
ganglion cells (RGCs) in the eye grow and project their axons towards their synaptic 
targets in the brain (Schmitt et al., 2006; for review, see Erskine and Herrera, 2007). The 
highly reproducible pattern of axons navigating along distinct trajectories suggests that 
axons are guided by cues along their journey (Tessier-Lavigne and Goodman, 1996). A 
well-established model for RGC development is chick; additionally, it is easily accessible 
during development. Chick RGC axons grow contralateral from the retina to synaptic 
targets in the tectum of the brain, the visual processing region in chicken. This precision 
is made possible by guidance cues to ensure neurons synapse at the correct target region 
(optic tectum in chicken and zebrafish or lateral geniculate nucleus and superior 
colliculus in mammals) followed by pruning to reorganize in the specific patterning of 
visual neurons (Sperry, 1963). As such, investigating how neurons within the visual 
system reach their synaptic target is an essential developmental model to uncover 
molecular cues that govern axon pathfinding that could be therapeutically 
induced/reduced after CNS damage to facilitate nerve regeneration.  
These RGC axons must travel long-distances through various tissues and interact 
with cues in the cellular environment, which is possible by a specialized structure at the 
leading edge of a developing axon known as a growth cone. A growth cone is a motile 
structure that is equipped with distinct receptors that provide communication with the 
extracellular environment to pioneer an axon (Tessier-Lavigne and Goodman, 1996). At 
the proximal part of the growth cone, this actin network is associated with microtubules. 
Growth cone motility is induced through the activation of cell surface receptors that 
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signal through complex pathways such as Rho and ROCK, which will ultimately control 
the assembly or disassembly of actin filaments (Huber et al., 2003). A growth cones must 
rapidly respond to its changing environment. A repertoire of guidance receptors is rapidly 
responding to the changing environment, thus allowing a growth cone to navigate 
towards its final target (Tessier-Lavigne and Goodman, 1996). The cues that a growth 
cone interacts with are known as axon guidance molecules. These axon guidance 
molecules are signaling molecules that activate receptors expressed on growth cones to 
guide the growing axons (Schmitt et al., 2006; for review, see Erskine and Herrera, 
2007). A growth cone’s dynamic behavior is responsive to multiple sources of 
information to ensure an axon reaches its target with an impressive level of accuracy. 
Additionally, the formation of neural networks means that precise navigation and 
connections are made with appropriate targets. The chemotactic cues allow for growth of 
axons over long distances which influences an array of signaling pathways, thus 
facilitating cytoskeletal and membrane remodeling of a growth cone.  
There has been significant work around axon guidance molecules within the 
visual system. These axon guidance molecules are characterized as either attractive or 
repulsive (for review, see Herrera et al., 2019). Guidance cues determine the route by a 
combination of attractive and repulsive cues that can be either localized and act at short-
range, or act over long distances (Tessier-Lavigne and Goodman, 1996; Dickson, 2002). 
For nearly 30 years, a spectrum of guidance cues has been identified. These are the major 
families, but there are other molecules too: semaphorins, ephrins, netrins, and slits (for 
review, see Reynes and Cook, 1995; Stoeckli, 2017; Stoeckli, 2018). Besides the 
expansion of guidance cues, the overall complexity of axon pathfinding is expanding, 
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such as our understanding that guidance cues can mediate more than one cellular 
response. Recent work suggests that a novel set of molecules, Lysophospholipids, may be 
axon guidance cues (Birgbauer and Chun, 2010; Fincher et al., 2014; Birgbauer, 2015).  
 
1.3 Lysophosphatidic Acid (LPA) 
Lysophospholipids are an important family of signaling molecules, and a 
prominent member is lysophosphatidic acid (LPA); it is a simple phospholipid composed 
of a phosphate, a glycerol, and a fatty acid. LPA is present in all eukaryotic tissues at low 
concentrations, and at higher concentrations (sub-micromolar range) in blood plasma. 
The signaling effects by LPA are mediated by G protein-coupled receptors (GPCRs). 
There are currently six known LPA-receptors in mammals known as LPA1-6, which are 
encoded by distinct genes named LPAR1-6 in humans and Lpar1-6 in mice and chick. 
These LPA-receptors play a pivotal role for cell proliferation, migration, angiogenesis, 
cytoskeletal changes, actin stress formation and cytokine and chemokine secretion (van 
Corven et al., 1989; Amano et al., 1997; Rivera‐Lopez et al., 2008; Sumida et al., 2010) 
and activate multiple G proteins, particularly G12/13, Gi, Gq, and Gs. Additionally, LPA is 
abundantly expressed in central and peripheral nerve tissues (Sato et al., 2005; Tanaka et 
al., 2004; Tanaka et al., 2006).  
LPA is produced from activated platelets, activated adipocytes, neuronal cells, 
and other cell types. There are at least two major pathways of LPA production. The first 
pathway is cleavage of Lysophospholipids (LPLs), for instance lysophosphatidylcholine 
(LPC) and lysophosphatidylserine (LPS), by lysophospholipase D/autotaxin. The second 
pathway involves hydrolysis of phosphatidic acid (PAs) by phospholipase A1 and A2 
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(Moolenaar, 2002; Pagès et al., 2001), which has been predicted to play a pivotal role in 
cell signaling (Aoki et al., 2008). However, mechanisms of LPA production in neuronal 
cell types are not well understood, although it is certain that LPA plays a pivotal role in 
many biological processes.  
Lysophosphatidic acid plays a role in a host of physiological and pathological 
processes. The first known in vivo biological function of LPA was the regulation of blood 
pressure (Sen et al., 1968; Tokummura et al., 1978). The nervous system is one the major 
regions for LPA receptor expression as it is expressed in the brain at relatively high 
concentrations (Sugiura et al., 1999). There has been significant work on gain- and loss-
of-function for LPA-receptors in the nervous system. LPA-receptors are expressed in 
most neural cell types including neural progenitors, primary neurons, astrocytes, 
microglia, oligodendrocytes, and Schwann cells (for review, see Noguchi et al., 2009). 
LPA signaling has been shown to influence numerous developmental processes in the 
nervous system: survival (Kingsbury et al., 2003), growth cone and process retraction 
(Campbell and Holt, 2001; Fukushima et al., 2000; Yuan et al., 2003), and proliferation 
(Kingsbury et al., 2003). Additionally, the role of LPA influences brain and vascular 
development (Estivill-Torrus et al., 2008; Teo et al., 2009), immune response (Ray and 
Rai, 2017), and reproduction (for review, see Beltrame et al., 2020). LPA also induces 
numerous cellular responses in a variety of cell types such as cell rounding, neurite 
retraction, proliferation, intracellular calcium mobilization and much more (Fukushima et 
al., 2001). In particular, LPA-receptors can activate Gα12/13 that leads to activation of 
GTPase RhoA, thereby signaling cytoskeletal rearrangement and cell rounding (Etienne-
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Manneville and Hall, 2002) that has been demonstrated to be essential for the guidance of 
a growth cone.  
Additionally, LPA has not been determined to be involved in axon guidance. 
However, previous research has demonstrated LPA to cause cultured retinal growth cones 
to collapse in the presence of LPA (Birgbauer and Chun, 2010; Fincher et al., 2014). This 
growth cone collapse response, where a RGC growth cone interacts with LPA and 
retracts (collapses) or steers away from this chemical cue, is similar to what is seen with 
other established axon guidance molecules (Schmitt et al., 2006). Thus, LPA could be a 
potential novel axon guidance molecule.  
 
1.4 LPA-receptors  
 Lysophospholipids (LPs), such as sphingosine 1-phosphate and lysophosphatidic 
acid are membrane-derived bioactive lipid mediators. Since the 1990s and early 2000s, 
identification of GPCRs has provided researchers with the framework to understand how 
LPs signal receptor-mediated functions. Many of the LP receptor genes have been 
identified as EDGs (Endothelial Differentiation Genes). In general, LP receptors share 
high amino acid similarities while also sharing similarities between GPCRs that signal 
other bioactive lipids such as endogenous cannabinoids or platelet-activating factor (for 
review, see Fukushima et al., 2001). It is now known that there are six bona fide LPA-
receptors (LPA1-6), five of which are high-affinity cognate receptors (LPA1-5).  
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1.5 LPA Receptor-1 
 LPA1 is the first receptor identified for its high affinity to LPA (for review, see 
Fukushima et al., 2001; Ishii et al., 2004). The mammalian (human, mouse, and rat) 
genes encode 41-kDA proteins consisting of 364 amino acids. LPA1 activates three of the 
major LPA pathways: Gαi/o, Gαq/11, and Gα12/13 (Fukushima et al., 1998; Ishii et al., 2000). 
There is high expression of Lpar1 in adult mice, which is found in brain, uterus, testis, 
lung, heart, and many other regions of the adult mouse (Contos et al., 2000; Ye, 2008). 
During embryonic development, Lpar1 is enriched in the brain and retina (Ohuchi et al., 
2008; Fincher et al., 2014) which has led to its focus as an important mediator in the 
developing nervous system. Lpar1 was found to be expressed in oligodendrocytes (CNS) 
and Schwann cells (PNS) that serve as the myelinating cells of the nervous system 
(Weiner et al., 1998; Weiner and Chun, 1999).  
 The attempts at targeted disruption of Lpar1 in mice resulted in several in vivo 
functions of this receptor (Contos et al., 2000). Lpar1(-/-) mice had nearly 50% lethality 
during the perinatal period, and ones that survived had reduced body size, craniofacial 
dysmorphism, and increased apoptosis in sciatic nerve Schwann cells (Weiner et al., 
2001; Contos et al., 2000).  
 
1.6 LPA Receptor-2 
 Lpar2 was first identified because of its homology with Lpar1 while investigating 
orphan GPCR genes, where it was revealed that Lpar2 had nearly 60% amino acid 
homology as Lpar1. LPA2 is a bona fide LPA receptor because it demonstrates high 
affinity for LPA (Bandoh et al., 2000). Similar to LPA1, LPA2 couples with three G-
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proteins, Gαi/o, Gα11/q, and Gα12/13. These various signals activate cellular events that 
include Ras, mitogen-activated protein kinase, Rac, diacylglycerol, and Rho (Fukushima 
et al., 1998). In chick, RT-PCR data shows that Lpar2 is expressed the developing brain 
and retina (Fincher et al., 2014). In mouse, the regions of high expression for Lpar2 is in 
kidney, uterus, and testis while moderately expressed in lungs. Additionally, it has lower 
expression levels in brain, heart, spleen, stomach, and thymus (Contos et al., 2000). In 
humans, LPAR2 is predominantly expressed in testis and leukocytes. Of issue is that in 
cancer cells, LPAR2 expression was found in several cases, which may indicate a role for 
mediating tumor growth for LPA2 (An et al., 1998).  
 
1.7 LPA Receptor-3 
 Similar to Lpar2, Lpar3 was discovered as an orphan GPCR by the use of 
degenerate PCR-based cloning and searches for homology (Bandoh et al., 1999). The 
most abundant expression of human LPAR3 is in heart, testis, prostate, pancreas, lung, 
ovary, and brain (Bandoh et al., 1999; Im et al., 2000), whereas in mice high expression 
is found in testis, kidney, lung, small intestine, heart, stomach, spleen, brain, and thymus 
(Contos and Chun, 1998). In chick, RT-PCR data shows that Lpar3 is expressed the 
developing brain and retina (Fincher et al., 2014). Similarly, with LPA1 and LPA2, LPA3 
couples with Gαi/o and Gαq to signal phospholipase C activation, Ca
2+ mobilization, 
adenylyl cyclase inhibition or activation, and mitogen-activated protein kinase activation 
(Ishii et al., 2000). Importantly, LPA3 does not appear to couple with Gα12/13 to signal 
Rho, which in turn, did not mediate cell rounding in neuronal cells and an explanation for 
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why LPA3 is not involved in LPA-induced growth cone collapse (Ishii et al., 2000; 
Birgbauer and Chun, 2010). 
 
1.8 LPA Receptor-4 
 The identity of LPA4 was originally from cloning of a putative receptors that were 
GPCRs (O’Dowd et al., 1997; Janssens et al., 1997) and was later established to have a 
specific affinity for LPA by ligand screening (Noguchi et al., 2003). Interestingly, LPA4 
is more closely related to P2Y purinergic receptors instead of the typical homology 
shared between LPA and S1P receptors. The unique characteristic of LPA4 is that P2Y 
purinergic receptors, which are GPCRs, are activated by nucleotides and nucleotide 
sugars. Meanwhile, LPA4 did not respond to any nucleotides or nucleosides (Janssens et 
al., 1997; Noguchi et al., 2003). LPA4 has a specific affinity for 18:1-LPA and following 
18:0-, 16.0, 14:0, and 1-alkenyl-LPA, respectively (Noguchi et al., 2003). However, there 
was not specificity for other lipids such as S1P or SPC (Noguchi et al., 2003).  
 In humans, expression of LPAR4 is abundantly expressed in ovary and is 
moderately expressed in brain, heart, small intestine, testis, prostate, colon, thymus, and 
pancreas (Noguchi et al., 2003). The predominant areas of expression in mice for Lpar4 
is in heart, skin, thymus, ovary, developing brain, and embryonic fibroblasts (Lee et al., 
2008; Lee et al., 2007). Importantly for this research, RT-PCR data shows expression of 
Lpar4 in the developing chick brain and retina (Fincher et al., 2014).  
 In LPA4 expression studies in cells, LPA induces cell rounding and stress fiber 
formation by activating the Gα12/13 and Rho/Rho-kinase pathways (Lee et al., 2007; 
Yanagida et al., 2007) that is also found for cells expressing LPA1, LPA2, and LPA5. It 
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has been reported that targeted disruption of LPA4 leads to embryonic lethality caused by 
disorganized blood and lymphatic vessels but not fully penetrant, as some animals do 
survive (Sumida et al., 2010). Also, Takara et al., (2017) found that LPA4 induces 
enhanced vascular network information and improves drug delivery into tumors that led 
to anti-tumor effects.  
  
1.9 LPA Receptor-5 
 The orphan GPCR, GPR92, was identified as LPA5 by its binding affinity to LPA 
(Kotarsky et al., 2006) and couples with Gα12/13 and Gq as well as increases cAMP levels 
(Lee et al., 2006). Structurally different from LPA1-3, LPA5 is also part of the P2Y 
(rhodopsin-GPCR) family like LPA4, which it shares 35% homology with LPA4 (Lee et 
al., 2006). Expression studies from murine tissue find Lpar5 in embryonic brain, small 
intestine, skin, spleen, stomach, thymus, lung, heart, and liver (Kotarsky et al., 2006; Lee 
et al., 2006). In LPA5 expressing cells, LPA has shown to induce neurite retraction and 
stress fiber formation by activating the Gα12/13 and increases intracellular calcium levels 
via Gαq (Lee et al., 2006). Interestingly, two other lipid-derived molecules (farnesyl 
pyrophosphate and N-arachidonylglycin) were found to bind to LPA5 (Oh et al., 2008). 
This study suggested that the two ligands have a different interaction with the binding-
pocket of LPA5. However, successive studies confirmed LPA5 to be a bona fide LPA-
receptor because of the ligand-receptor interactions with 18:1-LPA (Williams et al., 
2009; Yin et al., 2009).  
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1.10 LPA Receptor-6 
 LPA6 is a newly identified GPCR of LPA and is closely related to LPA4. 
Yanagida et al., (2009) presented the case for LPA6 because of its high sequence 
homology with LPA4, thus suggesting that LPA might be its ligand. Curiously, Yanagida 
et al., (2009) could not detect LPA-induced Ca2+ mobilization or cAMP level changes in 
their B103-p2y5 (rat neuroblastoma-LPA6) cells. However, since the validation of LPA6 
as an LPA receptor, LPA6 has been reported to be associated with several types of tumor, 
such as colorectal (Takahashi et al., 2017; Katkoori et al., 2012), liver (Mazzocca et al., 
2015; Sokolov et al., 2013), prostate (Ketscher et al., 2014), pancreatic cancer (Ishii et al., 
2015), and breast cancer (Tao et al., 2019). However, the role of LPA6 remains to be 
controversial since previous studies indicated that LPA6 might act as a tumor suppressor 
and inhibit migration, whereas others found LPA6 might act as a tumor facilitator 
(Takahashi et al., 2017; Katkoori et al., 2012; Mazzocca et al., 2015; Sokolov et al., 
2013; Ketscher et al., 2014; Ishii et al., 2015).  
  
1.11 LPA – A potential axon guidance molecule 
There has been a considerable amount of work investigating axon guidance 
molecules. At this point, there are many proteins that are established axon guidance 
molecules such as Ephs and ephrins, wnts, semaphorins (for review, see Erskine and 
Herrera, 2007). A hallmark for establishing inhibitory axon guidance cues is by its ability 
to induce growth cone collapse such as semaphorins. Recent evidence suggests a new 
class of signaling molecules might be potential axon guidance cues, which are 
Lysophospholipids (LP). One type of LP that has shown promise is lysophosphatidic 
 
P a g e  | 13 
 
acid. Jalink et al., (1993) found that LPA caused growth cone collapse and neurite 
retraction in rat pheochromocytoma (PC12) cells. Additional studies were also able to 
find similar effects by LPA on primary embryonic retinal axons in vitro from chick, 
Xenopus, and mouse (Fincher et al., 2014; Strochlic et al., 2008; Birgbauer and Chun, 
2010). The in vitro evidence is strengthened by the fact that Lpars1-4 and -6 are 
expressed in the developing chick retinal tissue (Fincher et al., 2014) and a structurally 
similar lipid sphingosine 1-phosphate (S1P) has been verified axon guidance molecules 
(Strochlic et al., 2008). Additionally, Birgbauer and Chun (2010) analyzed knockouts for 
Lpar1-3 in mice and found that Lpar1-3 were not required for cultured RGC growth cone 
response to LPA. Since Lpar1-4 and -6 are expressed in retina, the evidence is suggestive 
either Lpar4 or -6 as the mediator for RGC growth cone collapse in culture. However, 
based on ligand-receptor affinity assays, LPA6 has a low-affinity for LPA binding (Lee et 
al., 2009; Yanagida et al., 2009) which justifies Lpar4 as being the best candidate for 
mediating growth cone collapse for LPA. 
 
1.12 Assays for studying axon guidance 
 In vitro assays are important tools for investigating what molecules are assisting 
with neuronal connections to establish the brain during development. Additionally, in 
vitro studies provide a controlled environment during experimentation. The benefits of in 
vitro experiments include (1) working with an identified cell type, (2) the ability to test 
individual potential axon guidance molecules, especially when a molecule demonstrates 
repulsive cue-like qualities, and (3) the ability to observe growth cone motility and 
protein dynamics by live cell imaging. There are two common cell types that are used in 
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in vitro studies which are retinal ganglion cells and spinal cord neurons (dorsal root 
ganglion cells) in chicken, mouse, and Xenopus (Fincher et al., 2014; Gomez et al., 2003; 
Luo et al., 1993).  
  
1.13 Experimental Model for LPA4  
The aim of this thesis was to develop a CRISPR system to mutate Lpar4 in the 
developing chick retina to give a better understanding of how LPA mediates growth cone 
collapse of retinal ganglion cells, in hopes to better understand axon guidance. Chicken 
embryonic retinas are easily accessible which makes them an excellent model for study. 
Based on several studies, the evidence suggests that LPA may be a novel axon guidance 
molecule (Fincher et al., 2014; Birgbauer and Chun, 2010). The study by Birgbauer and 
Chun (2010) suggests that LPA1-3 are not key for LPA-induced growth cone collapse, 
while LPA5 is not expressed in the developing chick retina (Fincher et al., 2014) and 
LPA6 has a low affinity for LPA (Yanagida et al., 2009). Therefore, we hypothesize that 
LPA4 is the receptor that signals growth cone collapse in the presence of LPA. In order to 
investigate the in vivo role of LPA and axon guidance, we needed to establish a method 
for targeting LPA4.  
Genetic engineering for in vitro or in vivo studies has provided important insights 
into a plethora of receptor-ligand interactions. Specifically, CRISPR-Cas9 has been 
making groundbreaking advancements for gene-editing (for review, see Doetschman and 
Georgieva, 2017). CRISPR-Cas9 is establishing itself as the designer nuclease because of 
its ability to only require a short single-guide RNA (gRNA), which makes it target 
specific. For this research, CRISPR was designed to induce a double-stranded break to 
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DNA, thereby introducing short insertions or deletions at the cleavage site to make a non-
functional LPA4.  
To accomplish this, we used a technique known as electroporation that will insert 
DNA/RNA into stem/progenitor cells of the developing chicken retina (Islam et al., 
2012). The pulsed electric field will increase cell membrane permeability, and therefore, 
allowing for molecules that would not have been readily taken up by cells can now be 
introduced into the cellular environment. Due to the wide range of applications for 
electroporation (Neumann et al., 1982; Islam et al., 2012), the parameters can be vastly 
different: amplitude, duration, pulse number, and repetition rate. As such, we followed 
the same parameters established by Islam et al., (2012) to transduce plasmids into the 
developing chick retina. By combining our CRISPR system and electroporation, this 
research looks to investigate whether LPA4 is the receptor responsible for mediating 
LPA-induced growth cone collapse, to determine whether LPA is required for guiding 
and establishing the highly specific organization of visual neurons that govern axon 
pathfinding.  
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Chapter 2                 MATERIAL AND METHODS 
 
2.1 Design of gRNAs 
 We designed the oligonucleotides used as the gRNA in our CRISPR system 
through the MIT CRISPR website (http://crispr.mit.edu). It is a web based CRISPR 
design tool to simplify the selection process for a CRISPR guide sequence in a DNA 
input.  
From the gRNA sequences recommended by the MIT CRISPR algorithm, we 
added our own selected measures for our gRNAs (criteria based on Gandhi et al., 2017). 
First, we selected a sequence of 19 to 20 nucleotides in length and adjacent to an NGG 
proto-spacer motif (PAM) sequence. Second, and critically important, we compared the 
homology of our gRNA sequences to other Lpar genes to limit off-target effects. Lastly, 
we took into consideration of the gRNA targeting the locus at the 5’ or 3’ direction. 
Oligonucleotides were ordered from Eurofin Genomics as forward and reverse primers 
and annealed to produce double-stranded oligos. The annealed oligos were ligated into 
BsaII linearized U6.3>gRNA.f+e vector (Gandhi et al., 2017; addgene: 99139) (provided 
by Marianne Bronner) at the of the 5’ and 3’ overhangs.  
 
2.2 Ligation Reaction 
The plasmid supplied (U6.3>gRNA.f+e; addgene: 99139) was linearized with 
Bsal-HF with either 5’-GGAT-3’ or 3’-CAAA-5’ overhangs thus allowed us to clone in 
our annealed oligos into our vector. The ligation reaction incubated for 20 minutes at 
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room temperature (25-27°C). After incubation, high-efficiency 5-alpha Competent E. coli 
(DH5α; New England BioLabs) were transformed with the ligated gRNA vector. 
 
2.3 Transform Competent E. coli Cells 
High Efficiency Competent E. coli were transformed with the newly ligated 
gRNA vectors. SOC Medium is used during the transformation procedure. E. coli cells 
are spread on pre-warmed LB agar plates containing 100 µg/ml carbenicillin. The LB 
concentration for 500 ml was 5 g Tryptone, 2.5 g Yeast extract and 5 g NaCl. An efficient 
ligation reaction produced over a hundred colonies in total, which we diluted our 
transformation mixture to reduce the total number of colonies for screening. 
 
2.4 Plasmid Isolation 
To screen for successful inserts, we isolated plasmid DNA using Zymoresearch 
miniprep plasmid DNA purification kit. Transformed E. coli were left to grow in LB 
medium overnight. To determine if our oligos ligated into our vector, we PCR-amplified 
using U6 sequencing primers (5’-ATCGGCTAAGCGGGCCTAAG-3’) with gRNA 
reverse primers (Table 1). At this point, we confirmed that five of the gRNAs oligos were 
successfully cloned into the U6.3>gRNA.f+e vector. However, gRNA6 was not 
successfully cloned. Taken together, our newly cloned gRNA vector was ready to be used 
in the transfection protocol or to be stored at -20°C for later use. 
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2.5 Cell culture, and transfection of DF1-Cas9 Cells 
An immortalized chicken DF-1 fibroblast cells expressing Cas9 (DF1-Cas9; 
Gandhi et al., 2017) was obtained. The DF1-Cas9 cells were cultured at 37 °C in 5% CO2 
in DMEM (Hyclone) supplemented with 10% fetal bovine serum (Gibco) and 
penicillin/streptomycin (Hyclone). To test gRNAs, DF1-Cas9 cells were transfected with 
each of the previously cloned gRNAs. The DF1-Cas9 cells were seeded to be 80% 
confluent on the day of transfection. We used the cationic lipid-based FuGene-HD 
reagent (Promega). The DNA was added to a mixture with the FuGene-HD reagent in a 
4:1 ratio of FuGene-HD to plasmid DNA. We incubated our mixture for 10 minutes, and 
it was added to our cells and cells grew for 2 days before analyzing our transfected cells 
under fluorescence microscopy. After analysis, transfected cells were washed with sterile 
PBS. 
gRNAs gRNA Oligos Basepair length 
gRNA 1 
F 5’- GGATGGTTCCGGTCTCGTACCATT-3’ 
25 bp 
R 5’- AAACAATGGTACGAGACCGGAACC-3’ 
gRNA 2 
F 5’- GGATGTAATGGTACGAGACCGGAA-3’ 
25 bp 
R 5’- AAACTTCCGGTCTCGTACCATTAC-3’ 
gRNA 3 
F 5’- GGATGGGTCCTAATGGTACGAGAC-3’ 
25 bp 
R 5’- AAACGTCTCGTACCATTAGGACCC-3’ 
gRNA 4 
F 5’- GGATGGAACGGATAGACTATTGCA-3’ 
25 bp 
R 5’- AAACTGCAATAGTCTATCCGTTCC-3’ 
gRNA 5 
F 5’- GGATGTGCAATAGTCTATCCGTTC-3’ 
25 bp 
R 5’- AAACGAACGGATAGACTATTGCAC-3’ 
gRNA 6 
F 5’- GGATGCCTTTAAGTACAACCTGTA-3’ 
25 bp 
R 5’- AAACTACAGGTTGTACTTAAAGGC-3’ 
Table 1: Single-stranded DNA oligonucleotides with overhangs used to ligate into 
U6.3>gRNA.f+e. vector that will target Lpar4. 
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2.6 Cell Sorting 
 For analysis via cell sorting, the DF1-Cas9 cells were first harvested from their 
culture dish via Trypsin for 5 minutes at 37°C. The cells were washed twice with PBS 
with a centrifugation step in between for 5 minutes at 1500rpm. Cells were resuspended 
in phosphate buffered saline (PBS) (Invitrogen) with 0.5% fetal bovine serum (FBS) and 
0.1 mM EDTA at 1000 cells/µl (recommended by Nanocellect WOLFsorter). The cells 
were then filtered (50 µm) to remove aggregated cells and then stored on ice. Cell sorting 
was done following Nanocellect WOLFsorter manufacturer protocol. Each of the 
gRNA/tdTomato transfected cells were left on ice before DNA isolation.  
 
2.7 DNA Isolation of tdTomato-positive Cells 
 Sorted cells were pelleted via centrifugation for 10 minutes at 3600 rpm and the 
supernatant was removed. The pelleted tdTomato-positive cells were resuspended in a 
cell lysis solution (100 mM TrisCl, pH 8, 50 mM EDTA, 1% (w/v) sodium dodecyl 
sulfate) until viscus. The cell lysate was centrifugated at max speed for 3 minutes and the 
supernatant was transferred into a 1.5 ml Eppendorf containing 600 ul of isopropanol, 
mixed well, followed by a max centrifugation step for 1 minute at room temperature. 
Supernatant was removed and pellet washed with 70% EtOH followed by max speed 
centrifugation for 1 minute. Supernatant was removed and the DNA pellet was air dried. 
DNA was resuspended in nuclease-free H2O and incubated overnight at room 
temperature to solubilize genomic DNA before PCR-amplification.  
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2.8 PCR over Lpar4  
 Primers were designed for PCR using the Lpar4 genomic sequence UCSC 
Genome Bioinformatics website (NM_001278049 and chr4:13745611388213) and 
NCBI’s Primer-Blast, (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Using the 
following criteria: 1) the primers must have a Tm>55°C, and 2) The length of them 
should be between 18 and 22 base pairs and have a 45 to 60% GC content. Table 2 shows 
the forward and reverse primer target locus and the expected amplicon of PCR 
production for the single exon encoding Lpar4.  
 
PCR Target Forward and Reverse Primer PCR product size 
Lpar4 locus 
5’-ACCTGCATCAGCGTTGACCG-3’ 
296 bp 
3’-ACAGGTGGTGCTGGTGTTGG-3’ 
 
 
2.9 Genotyping 
Transfected cell DNA was used for PCR amplification using Q5 High Fidelity 
with Lpar4 locus primers. Amplicons were then purified (Zymo) and TA cloned into 
CloneJET PCR Cloning Kit (ThermoFisher) transformed into E. coli, clones selected, 
plasmid prep by miniprep and sent off for sequencing at Eurofins Genomics. 
 
2.10 Animals 
Fertilized chicken eggs were obtained from Tyson Farms. Eggs were incubated at 
39°C with rocking and humidity for 2 days until experimental procedures.  
Table 2. Design of primer to PCR-amplify over Lpar4 exon from genomic 
DNA of transfected DF1-Cas9 tdTomato-positive cells 
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2.11 Ex ovo Cultured Transfer  
Solo number 7 plastic cups were weighted with 35 mL of sterilized distilled-H20 
before a 4 cm-deep plastic hammock with Saran brand plastic wrap was made and 
secured with a rubber band. Cup lids were given single puncture for air flow and the cups 
and lids were UV sterilized for 90 minutes. On embryonic day two (E2), embryos were 
ex ovo cultured in the plastic cups by cutting an opening to carefully transfer entire 
contents of eggs into ex-ovo cups and placed into 39°C incubator with water for 
humidity. 
2.12 Injections and Electroporation 
Embryos in ex ovo culture were injected into the subretinal space with GFP and 
tdTomato plasmids using 0.05% fast green to visualize injection and electroporated at 
embryonic day-3 using a BTX ECM 830 Electroporation Generator System that was set 
to 5 pulses of 15V for 50 ms with 950 ms intervals as previously described (Islam et al., 
2012). For co-electroporation experimentation, the concentration of GFP plasmid was at 
2.9 μg/μL and tdTomato 1.2 μg/μL. For Lpar4 knockout experiments, the subretinal 
space was electroporated with 2 μg/μL CAGG> nls-Cas9-EGFP, 1.5 μg/μL U6.3 > 
Lpar1gRNA1 and 1.5 μg/μL tdTomato. Electroporated embryos were allowed to develop 
until embryonic day 6 until retinal dissections described below.  
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2.13 Retinal Dissection, Imaging, and Retinal Culture 
Retinas were dissected by removing the iris to expose the retina from 
electroporated embryos on embryonic day 6 (Hamburger and Hamilton stages 28–29) 
under a fluorescence stereoscope. The fluorescent retinal was isolated, flat mounted on a 
slide in 90% glycerol, and prepared for confocal imaging using an Olympus FV1000 
laser-scanning confocal microscope.  
The fluorescent retinal tissue was cut into explants. Explants were cultured in 
Ham’s F12 media (Hyclone) supplemented with N2 and B27, 1 mM sodium pyruvate, 0.5 
mg/ml ascorbic acid, 10 ng/ml CNTF, 50 ng/ml BDNF, and penicillin-streptomycin in a 
37°C, 5% CO2 incubator. After overnight incubation on 0.1 mg/ml poly-D-lysine and 10 
µg/ml laminin-coated dishes, cultures were fixed in 4% paraformaldehyde.  
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Chapter 3              RESULTS  
 
We have designed a CRISPR-Cas9 system that mutates Lpar4 at early developmental 
stages to target retinal ganglion cells, starting with cloning of gRNAs to demonstrate 
proof of principle while optimizing delivery of plasmids into the developing chick retina.  
3.1 Designing gRNAs for Lpar4 mutations in chick embryos 
We designed guide RNAs (gRNAs) that targeted the coding sequence of Lpar4. 
By obtaining sequencing data for Lpar4 locus 
(http://www.ncbi.nlm.nih.gov/nuccore/XM_015278221.2), we knew that LPA4 is 
produced by a single exon, which meant that we could not target intron-exon boundaries. 
Therefore, we made the decision to target the first half of Lpar4 coding sequence to 
increase our chances of a mutation that would result in a non-functional LPA4. If we had 
targeted the second half of the Lpar4 coding sequence, it might be possible to produce a 
functional LPA4. It was important that we had two validated gRNAs that have high 
mutation frequency for our in vitro assays so we could compare whether two gRNAs 
produce the same growth cone collapse data. If the data was similar, then we would be 
confident that LPA4 is mediating LPA-induced growth cone collapse rather than an off-
target effect from our gRNA.  
The web based CRISPR design tool allows for simplifying the selection process 
for a CRISPR guide sequence. It identifies any sequences similar to other targets while 
highlighting gRNAs with high specificity. When presented with multiple gRNA 
sequences, we checked homology between the other LPA-receptors. What we found is 
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that there are multiple regions with high homology (Li et al., 2009), and are region of 
interest were areas of minimal homology. By pinpointing regions with the least 
homology, we were confident that off-target effects for the other LPA-receptors would be 
rare. We did have our sights on targeting a region where LPA is predicted to bind; 
however, there was high homology between the other LPA-receptors (Li et al., 2019). In 
addition to our own gRNA design parameters, Marianne Bronner’s lab provided us with 
their own gRNA selective measures that would reduce off-target effects and improve 
gRNA efficacy in the developing chick (a CGG or TGG PAM sequence; Gandhi et al., 
2017). At this point, we were confident with our approach before importing our Lpar4 
sequence into the MIT CRISPR Program for preliminary gRNA selection, while 
considering the guidelines provided by Marianne Bronner’s lab. We were able to select 
six gRNAs that fit our criteria (Fig. 1). Oligonucleotides for Lpar4 guide sequence were 
ligated into our vector and transformed into E. coli competent cells. Our vector 
(U6.3>gRNA.f+e.) has a chicken U6 promoter (U6.3) and has a modified gRNA ‘F+E’ 
scaffold that contains a ‘flipped’ (F) Adenine-Uracil downstream of the protospacer and 
an ‘extended’ (E) Cas9 stem handle to improve RNA polymerase III-mediated gRNA 
transcription that will help stabilize the interaction between Cas9 and gRNA (Gandhi et 
al., 2017).  
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To verify whether we had successful clones, we tested for inserts by colony PCR 
using U6 sequencing primers and gRNA reverse primer producing a 176 bp product (Fig. 
2). Up to this point, we confirmed that five of the gRNAs oligos were successfully cloned 
into the U6.3>gRNA.f+e vector. However, gRNA6 was not successfully cloned. Taken 
together, our newly cloned gRNA vector was ready to be used to be validated for 
CRISPR mutation.  
Figure 1. Design of gRNAs to mutate Lpar4 using the MIT CRISPR Program. (A) 
The seed sequences for each of the selected gRNAs to target Lpar4. (B) Protein 
sequence of chicken LPA4 with yellow regions indicating GPCR transmembrane 
domains. Light blue arrows indicate guide RNA target sequences and arrow direction 
is related to direction of targeted DNA sequence (5’ or 3’) (Fig. 1B, adopted from 
Eric Birgbauer). 
A) 
B) 
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3.2 Transfection of DF1-Cas9 cells, sorting of tdTomato-positive cells, DNA 
isolation for PCR-amplification of Lpar4 
By using an immortalized chicken fibroblast cell line that expresses Cas9 (DF1-
Cas9; Gandhi et al., 2017), we wanted test our gRNAs on Lpar4. We co-transfected 
tdTomato with our gRNA plasmid because our gRNA plasmid did not have a marker for 
analyzing transfection (Fig. 3), which tdTomato also served as a mechanism for selecting 
our gRNAs cells by cell sorting. We optimized our transfection ratio from 3:1 to 4:1 
(FuGene-HD: plasmid DNA) finding that the 4:1 ratio is significantly better at 
transfecting our DF1-Cas9 cells.  
 
 
 
Figure 2. Agarose gel electrophoresis of 
successfully cloned gRNAs colonies 
after PCR-amplification. Testing for 
successful ligation of U6.3>gRNA.f+e. 
vector with annealed gRNA primers was 
done using U6 sequencing primers with 
gRNA reverse primers. Indicated in 
lanes 1-5 are gRNAs 1-5, respectively. 
PCR products are 176 bp and the MW 
marker is indicated by MW with bands 
at 200 and 100 bp.   
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To be certain that all tdTomato-positive cells were co-transfected with gRNA 
plasmid, a 1.5:1 ratio molecules of gRNA plasmid DNA to tdTomato plasmid was used 
in the DNA mixture for transfection. It was critical to have a higher concentration of 
gRNA plasmid DNA compared to tdTomato to ensure all tdTomato-positive cells 
contained gRNA plasmid DNA. We were able to produce were transfection efficiencies 
ranged from 6.6 to 17.6% for tdTomato-positive cells (Table 3). Additionally, from prior 
cell sorting attempts, efficiency of transfection was vital in order to get a quantifiable 
amount of DNA that could be used for PCR-amplification.  
 
 
 
 
Figure 3. Transfection of 
gRNA and tdTomato 
plasmids into DF1-Cas9 
cells. To visualize a 
successful transfection, 
cells were imaging via 
fluorescence microscopy. 
Transfection consisted of 
cloned U6.3>Lpar4.gRNA 
and tdTomato plasmids .  
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DF1-Cas9 Cells and 
gRNA transfected with 
tdTomato 
Approximate total 
number of cells 
Number of 
tdTomato-positive 
cells 
Transfection 
Efficiency 
percentage 
Lpar4.gRNA1 3,000,000 539,650 17.9% 
Lpar4.gRNA2 3,000,000 294,212 9.8% 
Lpar4.gRNA3 3,000,000 319,649 10.6% 
Lpar4.gRNA4 3,000,000 198,506 6.6% 
Lpar4.gRNA5 3,000,000 245,447 8.2% 
   
Table 3. Analysis of FACS sorted DF1-Cas9 tdTomato-positive cells. gRNA and 
tdTomato plasmids were transfected in DF1-Cas9 cells then were sorted by FACS. 
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After cell sorting tdTomato-positive cells and DNA isolation, we PCR-amplified 
over our targeted Lpar4 region. Gel electrophoresis was to confirm we had PCR-
amplified over Lpar4 (Fig. 4).  
 
 
We isolated our PCR products and cloned it to isolate plasmids for sequencing. An issue 
we ran into was successfully ligating our PCR product into our cloning kit. After multiple 
attempts, we were able to successfully ligate our PCR product after increasing our 
concentration of product and during cloning. We followed the CloneJet transformation 
protocol and we were able to produce a high number of transformants. Transformants 
were grown overnight and plasmid DNA was isolated following ZymoResearch miniprep 
plasmid DNA protocol. We sent off plasmid DNA for sequencing to Eurofin Genomics. 
A range of different deletions were identified from each of the gRNAs (Fig. 5). What we 
found that gRNA 1 produced mutations 7 out of 7 sequences, gRNA 2 had 8 out of 8 and 
both gRNAs had mutations ranging from 2 bp to 20 bp deletions, whereas gRNA 3 had a 
Figure 4. Agarose gel electrophoresis 
after cell sorting of tdTomato-positive 
cells and PCR-amplified DNA for 
Lpar4. Shown in Lane 1 is the MW 
marker indicated by 300 and 200 bp, 
respectively. Successful PCR products 
are shown in lanes 2-6, which are 
gRNAs 1 to 5, respectively, and 
indicated by PCR product of 296 bp.   
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mutation 4 out of 6 sequences. Sequence results for gRNA 4 and 5 have not been 
analyzed due to trouble shooting issue when prior sequencing attempts were done, but 
analysis of gRNA 4 and 5 may be done in the future. Furthermore, the mutation events 
we analyzed from gRNA 1 and 2 were unique, which indicated that the mutation events 
we sequenced were independent from each other and were not from the clones. Taken 
together, these results confirm that we have designed robust gRNAs that mutate at the 
precise Lpar4 locus as expected.  
Figure 5. CRISPR-Cas9-
mediated mutation of Lpar4 
from transfected DF1-Cas9 
cells. Shown in red lettering is 
the normal DNA sequence of 
Lpar4. Below is the sequence 
of individual colonies from 
our transformed gRNAs. The 
number of excised nucleotides 
is represented in (bp). 
Mutations from gRNA 1 
reveal that all sequence results 
had a mutation of various 
sizes, which was also found 
from gRNA 2 sequences. 
Lastly, gRNA 3 did not 
produce mutations in every 
sequence. Dashed lines 
represent excised nucleotides. 
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3.3 Optimization of injection and electroporation into the subretinal space of the 
chick retina   
Before injecting our CRISPR system into the chick retina, we needed to demonstrate 
that our methodology of injection and electroporation could transduce retinal ganglion 
cells. Additionally, we needed to validate that co-electroporating multiple plasmids could 
be introduced into the same cell. We injected tdTomato and GFP plasmids into the 
subretinal space of the chick embryo as shown in figure 6 using fast green to visualize 
injections. Initial retinal injections were done into the retinal cavity, which only 
transduced a few retinal cells (data not shown). Islam et al., (2012) established that it is 
important to inject into the subretinal space for transducing retinal cells.  
 
 
 
 
 
 
 
Figure 6. Visualization of a chicken embryo at day-3 under a stereoscope to locate the 
retina. (A) Chick embryo before injection into the subretinal space. (B) A successful 
injection of plasmids into the subretinal space and fast green is included to visualize 
injection. 
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For our injection procedure, embryos were cultured ex ovo at Hamburger and 
Hamilton (HH) stages 6-10. At HH15-18, we injected a GFP and tdTomato plasmid into 
the subretinal space and transduced via electroporation (Islam et al., 2012). Three days 
later, retinal tissue was analyzed for transduction of GFP and tdTomato. We went 
through many trials of optimizing our injections and electroporations. Initially, our 
plasmid concentration was 800 ng/µl which is when we were unable to find transduced 
retinal tissue. After increasing our plasmid DNA concentrations to above 1.5 µg/µl we 
had a robust increase in the area of retina that was transduced (Fig. 7). We were able to 
transduce a substantial portion of the retina (Fig. 7B and C). 
 
 
 
 
 
 
 
 
 
 
 
To confirm that the retinal tissue had been co-electroporated with both plasmids 
into the same cells, we examined our retinal tissue via fluorescence confocal microscopy. 
Before confocal imaging, isolation of GFP/tdTomato retinal tissue was excised and flat 
amounted on a microslide slide. Confocal imaging revealed high transduction of GFP and 
Figure 7. Fluorescence stereoscope examination of isolated embryonic day-6 retinal 
tissue to visualize co-electroporation of tdTomato and GFP plasmids in embryonic 
chick retina. A) Flat mounted E6 retina under brightfield to visualize retina. (B to C) 
Same orientation as (A) but under the red channel (B) or green channel (C) to visualize 
where the plasmid transduction was localized in the retina. Overall, co-localization 
seems apparent between tdTomato and GFP plasmids in the chick retina.   
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tdTomato labeled retinal cells (Fig. 8A and B). Next, we asked whether the GFP and 
tdTomato were expressed in the same retinal cells by overlaying the images (Fig. 8C) 
Importantly, the retinal tissue isolated was injected with a 3:1 ratio of GFP to tdTomato 
plasmids, so we predicted that there would be a higher number of GFP expressing cells. 
We found that almost all the tdTomato-positive cells expressed GFP (i.e., indicated by 
orange-yellow cells) (Fig. 8C). Confocal analysis demonstrated that we are able to 
transduce multiple plasmids into the same cells at early developmental stages in the 
retina.  
 
 
 
 
 
 
 
 
 
 
Figure 8. Confocal imaging to 
visualize co-transfection of plasmids 
at the cellular level. Imaging was done 
at 40x to enhance view of  tdTomato 
and GFP co-electroporated retinal 
cells from embryonic chick. A) 
Visualization of GFP and (B) 
tdTomato transduced retinal cells. C) 
Overlay of same orientation taken for 
(A and B) to analyze co-transfection 
efficiency.  
B 
C 
A 
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In order to demonstrate that RGC growth cones could be transduced, we proceeded 
to do explant cultures on our transduced retinal tissue. Isolated retinal tissue was cut into 
explants and cultured overnight. We observed RGC growth cones could be transduced 
(Fig. 9B). One of the issues we found was being able to produce a substantial number of 
growth cones that expressed GFP. The way we overcame this issue is by increasing the 
concentration of plasmid DNA during retinal injections. These results provide us with 
confidence that our technique of retinal injection with electroporation will produce RGC 
growth cones that can be analyzed. 
  
Figure 9. Electroporated E6 chick retina in culture and imaged under fluorescence 
microscopy to identify GFP expressing RGC neurites. A) Visualization of retinal explant 
and RGC neurites branching from the explant. B) An individual RGC axon and tipped by a 
growth cone (white arrow), thus demonstrating subretinal electroporation can transduce 
RGCs.   
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3.4 Injection and electroporation of CRISPR-Cas9 construct with tdTomato into 
the subretinal space of the developing chick retina  
Once we established proof of principle for our CRISPR gRNAs and cultured 
transduced explants, we were ready to introduce our CRISPR-Cas9 construct into the 
embryonic chick retina. Transduction into RGCs has been established (Fig. 7 and 8; 
Islam et al., 2012), in addition to RGC growth cones (Fig. 9). Recent attempts to 
introduce our CRISPR system were unsuccessful due to an issue with embryo viability. 
As a result, future attempts will be conducted.  
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Chapter 4                   DISCUSSION  
 
LPA is an extracellular signaling molecule that has demonstrated its potency to be 
a potential repulsive-like axon guidance molecule. These effects have been shown in 
many neuronal cell types and in primary neurons (Jalink et al., 1993; Kozma et al., 1997; 
Tigyi et al., 1996a and b; Fincher et al., 2014; Birgbauer and Chun, 2010). The effect of 
LPA on growth cone collapse is present at the nanomolar range and activates neurite 
retraction via the Rho pathway. There are several GPCRs that LPA signals (LPA1-6). 
Previous research has attempted to identify which receptor is responsible for mediating 
neurite retraction in mice and determined that LPA1-3 were not required (Birgbauer and 
Chun, 2010). During that time, LPA4 and LPA5 were recently identified (Noguchi et al., 
2003; Kotarsky et al., 2006; Yanagida et al., 2009) making them likely candidates for 
mediating LPA-induced growth cone collapse. However, based on RT-PCR data from 
embryonic chick retina, we know that LPA5 is not expressed in the retina (Fincher et al., 
2014). More recently, LPA6 has been shown to be expressed in the developing mouse 
brain (Suckau et al., 2019), although it was found to have a much lower affinity for LPA 
than the other LPA receptors (Yanagida et al., 2009). Accordingly, we chose to target 
LPA4 as the receptor mediating LPA-induced growth cone collapse.  
Despite the increasing specificity of CRISPR-Cas9 technology, there are still 
some important considerations requiring comprehensive studies. Specifically, gRNAs 
have tended to have mismatch tolerance, which is when Cas9 cleaves off-target sites for 
sequences that are similar to target genes; hence, off-target effects. Efforts to increase 
specificity have been conducted to improve gRNA design, species-specific promoters, 
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and optimized delivery methods (Gandhi et al., 2017). In our study, our species-specific 
promoter and gRNA target sequences were optimal for our target locus. While following 
gRNA design criteria from Gandhi et al., (2017), we ensured that we would have minimal 
off-target effects among the other Lpars by targeting a sequence with the marginal 
homology (Lee et al., 2009). Furthermore, by using two gRNAs for investigating whether 
LPA4 is the receptor responsible for mediating LPA-induced growth cone collapse, we 
would be confident with our data if it were reproducible.  
We have confirmed that our CRISPR system mutates Lpar4 in a chicken cell line. 
The effect of our gRNA 1 and 2 supports high efficacy of mutation for Lpar4. We have 
not shown the impact of our CRISPR system in a growth cone collapse assay. However, 
our CRISPR vectors were specifically designed to be chicken-specific and presented high 
efficacy (Gandhi et al., 2017), which makes us confident that our designed CRISPR 
gRNAs will mutate Lpar4 in the developing chick retina. Moving forward with growth 
cone collapse assays should determine whether our hypothesis that LPA4 is the receptor 
that mediates LPA-induced growth cone collapse in vitro.  
In addition to validating our gRNAs, we optimized our injections and 
electroporations in the developing chick retina. After tweaking plasmid DNA 
concentrations, we have resolved that any concentration above 1.5 µg/µl will provide 
ample number of transduced retinal cells, and that higher concentrations may transduce 
more cells based on preliminary results shown during our attempts at testing various 
DNA concentrations. Moving forward, 2.0 µg/µl for Cas9 and gRNA plasmid should be 
sufficient with 1.5 µg/µl of tdTomato to ensure the number of molecules of Cas9 and 
gRNA plasmids will be more than tdTomato. This is critical when isolation of tdTomato-
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positive retinal tissue takes place so it is certain that it will include both Cas9 and gRNA 
plasmid DNA. Our controls during CRISPR experimentation would consist of our control 
gRNA plasmid that has a scrambled sequence with no homology for any chick gene, 
Cas9 plasmid, and tdTomato. Isolated retinal tissue would be isolated from both Lpar4 
and control gRNA and cut into explants and cultured in separate wells. The next day, 1 
µM LPA would be added to each well and treated for 10-15 minutes followed by 
fixation. Since we are analyzing transduced RGC neurites, we must use fluorescence 
microscopy for analysis. To determine whether LPA4 is responsible for mediating LPA-
induced growth cone collapse, a growth cone count would be done to calculate the 
percentage of collapsed to non-collapsed growth cones. This is the standard method when 
doing growth cone collapse assays to determine statistically whether any significance is 
found (Birgbauer and Chun, 2010; Fincher et al., 2014). To reduce bias, a blind count 
would be done so the person does not know which well contained Lpar4 gRNA.  
Besides growth cone collapse data, a data point that we do not have is whether our 
gRNAs mutate RGCs. However, the way that we could obtain this data is by cell sorting. 
Notably, it has been established that primary murine RGCs are able to be isolated by cell 
sorting (Chintalapudia et al., 2017). To move forward with this approach, there are 
required factors for the success of isolating transduced retinal cells by cell sorting: 1) sort 
efficiency, this would depend on the cell sorter used; 2) optimal combination of 
fluorochromes to minimize noise, tdTomato has shown to produce sufficient results; and 
3) cell sorting setup. It is also critical to maintain the sample at 4°C when sorting large 
numbers of cells (Chintalapudia et al., 2017). Therefore, if we followed our same 
injection technique, we could prepare transduced retinal tissue for cell sorting using our 
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method for sorting DF1-Cas9 cells. A critical factor is knowing whether many cells has 
been collected. If the Trypsin and EDTA steps were done effectively, a cell count via 
hemocytometer would serve to quantify cells and indicate whether we have successfully 
isolated our retinal tissue into individual cells. What would be expected is that multiple 
retinas would be needed to ensure a large quantity of tdTomato-positive cells are 
available. The outcome of this experiment would provide proof that our gRNAs mutate 
chick retina cells.  
There are three possible results from our growth cone collapse data. First, and 
based on our hypothesis, we should find Lpar4 mutant growth cones should not collapse 
in the presence of LPA. This means that when LPA is added to their environment, we 
should find that only a small percentage (10-15%) have collapsed. The reason for 10-15% 
is that there are always growth cones that will collapse even without an LPA-treatment 
(Birgbauer and Chun, 2010; Fincher et al., 2014). If this were the outcome, we would 
assess that LPA4 is the receptor mediating LPA-induced growth cone collapse. Similarly 
to Birgbauer and Chun (2010), the second outcome would be that there is still an equal 
percentage of growth cones that collapse in the presence of LPA. Indicating that LPA4 
does not have a role in LPA-induced growth cone collapse. Lastly, the function of LPA4 
may work redundantly with other LPA-receptors to mediate LPA-induced growth cone 
collapse. In other words, it is possible that LPA1-4 or -6 are working together to cause 
growth cone collapse. Notably, LPA3 was found to not couple with Gα12/13 which is the 
pathway for mediating neurite retraction and cell rounding.  
If we were to obtain Lpar4 results showing that LPA4 is the receptor responsible 
for LPA-induced growth cone collapse, then we would be a step closer to validating a 
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new axon guidance molecule. The next question would be to verify how the mutation of 
Lpar4 would alter RGC axon pathfinding in vivo. We know that RGCs house their cell 
bodies in the retina which then extend their axons through the optic disc to bundle and 
form the optic nerve. Already at this early stage of development, guide molecules are 
signaling RGC axons as they form the optic nerve. RGC axons from both eyes form the 
two optic nerves and grow toward each other where they converge at the optic chiasm, an 
x-shaped fiber pathway. The axons continue their contralateral projections to the tectum 
where they will find their synaptic targets and form the connections necessary for eye-to-
brain communication.  
Along the journey for RGC axons, there are a variety to axon guidance cues that 
their growth cones will encounter. Some guidance cues have been identified to signal 
RGC axons at the midline (chiasm) (for review, see Guillery et al., 1996), whereas other 
assist in the organization at the tectum (Luo et al., 1993). If our LPA4 growth cone 
analysis presented results that demonstrate this is the receptor responsible for LPA-
induced growth cone collapse, we would pursue in vivo imaging. By following RGC 
axons along their journey to tectum, we can ask the question: where is LPA mediating 
axon guidance? By using our established injection and electroporation method, chick 
embryos would develop until embryonic day-9, -10, -12, or -15. Using dye tracing and 
light sheet microscopy, the trajectory of RGC axons as they navigate to the tectum would 
be analyzed. Since we know that RGCs organize in a highly specific manner in the 
tectum, we could visualize whether Lpar4 mutant axons reach their appropriate targets. If 
aberrant axons were found in the native contralateral projections, we would hypothesize 
that LPA is mediating axon guidance near their synaptic targets. Importantly, autotaxin 
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(ATX) — the major enzyme converting lysophosphatidylcholine into LPA — is 
expressed in the developing chick brain at HH stage 8 to 36 (Ohuchi et al., 2008). ATX 
was expressed in the entire region of the apparent diencephalon as well as in the 
hindbrain. Taken together, if ATX is producing LPA in the hindbrain then it is possible 
that LPA is mediating axon guidance for RGC axons to not go beyond their target.  
If axons were found to go ipsilateral then that would lead us to hypothesize that 
LPA is mediating axon guidance at the optic chiasm, which is when RGC axons from 
both eyes converge and are signaled to begin their journey contralaterally. Thus, this 
would suggest that LPA has a pivotal role for mediating RGCs to extend towards their 
native contralateral region. If this was so, we know that RGC axons begin their long-
journey between embryonic day-5 and -6. What could be done is using fixed embryos at 
various stages where RGC axons reach the optic chiasm to visualize the initiation of RGC 
axons projecting both contralaterally and ipsilaterally using light-sheet microscopy. Of 
interest, we have labeled RGCs by injecting Alexa Fluor 555 conjugated Cholera Toxin 
Subunit B (CTB) (red) into the developing chick retina and visualized their contralateral 
projects to where they synapse in the left tectum (unpublished data). Since our CRISPR 
system would include tdTomato, our transduced RGC axons would be identified under 
red fluorescence. Importantly, we also include our control gRNA plasmid that would 
result in normal topographic mapping of RGCs in the tectum. We would use CTB – 
Alexa Fluor 496/433 (green) to inject into the non-CRISPR eye to visual those RGC 
axons as green. By each eye revealing either green or red RGC axons and Lpar4 mutated 
RGC axons began developing ipsilaterally, we might be able to see whether the mutated 
RGC axons would synapse in the right tectum. Since we know that the organization of 
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RGCs is highly specific (Feldheim and O’Leary, 2010; Rapacioli et al., 2011; Scicolone 
et al., 2006; Scicolone et al., 1995), it would be intriguing to determine whether the 
ipsilateral projections could successfully synapse in the right tectum. Consequently, if 
neural connections were made then the eye-to-brain communication would be distorted.      
The next major possible outcome would be that our growth cone collapse assays 
would not present the findings that LPA4 is the receptor mediating LPA-induced growth 
cone collapse. This would be revealed by a high percentage of collapsed Lpar4 mutant 
growth cones when doing LPA treated in vitro assays. These results would be a 
continuation to the findings by Birgbauer and Chun (2010), where LPA1-3 in mice did not 
alter RGC growth cone collapse. The hypothesis that LPA6 is responsible for mediating 
growth cone collapse would then be valid; however, another set of experiments should be 
done prior to focusing on LPA6 since it was shown that LPA-binding could only be 
detected at high concentrations (Yanagida et al., 2009). The hesitancy to focus on LPA6 
is that the concentration of LPA that induces growth cone collapse is present at the 
nanomolar range, whereas the binding affinity of LPA6 to LPA is found at the 
micromolar range. To this end, we would set our sights on LPA receptor redundancy.  
The mechanism of redundancy between one or more LPA-receptors has not been 
identified, although it was hypothesized (Birgbauer and Chun, 2010). To investigate 
whether multiple LPA receptors are responsible for mediating LPA-induced growth cone 
collapse would mean cloning gRNAs for Lpar1-2 and -6. A major reason for not focusing 
of LPA3 is because to induce growth cone collapse, or neurite retraction, LPA signaling 
uses the Gα12/13 pathway; however, LPA3 does not couple with Gα12/13. The criteria used 
for our Lpar4 gRNAs would be considered as well as following the same steps for 
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screening gRNA efficacy. There are two ways to approach the question on LPA-receptor 
redundancy. 1) We would clone gRNAs into their own plasmid, which would mean 
transfecting or injecting an additional plasmid using our current CRISPR system; and 2) 
we would clone in another gRNA sequence into gRNA 1 and 2 vectors. This second 
method would be optimal since the addition of another plasmid could reduce the 
efficiency of our delivery system. It is been established that multiple gRNAs to target 
different genes is possible (Sakuma et al., 2014). Intriguingly, Sakuma et al., (2014) were 
able to incorporate seven gRNAs and one Cas9 nuclease as a single vector for their 
studies. Based on this information, the foremost approach would be to clone in an 
additional gRNA to gRNA 1 and 2 vectors for redundancy investigation. There is a 
chance that more than two LPA-receptors are mediating growth cone collapse, which 
cloning in gRNAs for each of the LPA-receptors into the U6.3>gRNA.f+e. vector could 
be done with additional efforts.   
If the hypothesis that redundancy is occurring between LPA-receptors, then it 
would be necessary to mutate all Lpars and see whether LPA still causes growth cone 
collapse. To do so, each of the known LPA-receptors expressed in the developing chick 
retina (Lpar1-4 and -6) would need to be targeted. If this did not result in  a change for 
the percentage of growth cones that collapse or merely a minimal reduction for LPA-
induced growth cone collapse, then a possible explanation is an orphan GPCR has yet to 
be deemed as an LPA-receptor is mediating growth cone collapse. This outcome would 
take measures at doing homology comparisons to known LPA-receptors, LPA binding 
assays, and the many other approaches used to classify an LPA-receptor. Still, there is 
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much work to be done with the known LPA receptors and investigating which receptor 
causes LPA-induced growth cone collapse.  
The outcome of this research was to identify a receptor that mediates growth cone 
collapse in the presence of LPA. By identifying the receptor responsible for LPA-induced 
growth cone collapse, we are providing critical knowledge towards future nerve 
regeneration treatments such as treatment for glaucoma patients, optic nerve injuries, or 
even spinal cord injuries. At the site of a lesion, LPA is present at micromolar levels to 
help blood clotting (Aoki et al., 2002). If the lesion causes damage to a nerve, then there 
needs to be a mechanism for that nerve to regenerate and make proper synaptic 
connections again. It has been established that LPA-induced growth cone collapse is at 
the nanomolar range (Birgbauer and Chun, 2010). Consequently, if LPA is responsible 
for mediating axon guidance then the levels of LPA at a lesion site are too great for a 
regenerating nerve to overcome since the inhibitory effects shown in in vitro studies is 
potent. Additionally, future studies will be necessary to determine whether LPA has the 
same physiological responses transitioning from developmental stages to adult. By 
identifying the receptor responsible for this collapse, there is hope that by silencing LPA4 
at the lesion site would aid nerve regeneration.  
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